Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 12.25%, which has investors questioning if this is right time ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Pemphigus is divided into two major subtypes: pemphigus vulgaris and pemphigus foliaceus. Oral corticosteroids are the primary treatment modality for pemphigus, while other therapeutic options ...

Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

In contrast to pemphigus vulgaris, PF does not usually involve the mucous membranes and is associated with less morbidity and lower mortality. Treatment involves topical corticosteroids and ...

A host of concerns weighed on Immunovant’s stock price, the most critical of which was competitor argenx SE’s failure in pemphigus vulgaris, which has raised questions about the addressable ...

As of Feb. 13, Cabaletta has enrolled 26 patients across the RESET program, which consists of six trials in IIM, SLE, SSc, generalized myasthenia gravis, multiple sclerosis and pemphigus vulgaris ...

A host of concerns weighed on Immunovant’s stock price, the most critical of which was competitor argenx SE’s failure in pemphigus vulgaris, which has raised questions about the addressable ...